Column

Editor's Page

Predictive Methodologies to Better Manage Costs of Innovative Therapies

06/18/2019

Novel innovations in cell and gene therapies mark a new era in medicine whereby durable remission, and potentially cures, are within reach for several diseases. These advancements are clearly beneficial and have been...

Novel...

06/18/2019

Journal of Clinical Pathways

Editorial

The Real-Life Patient Impact of Pharmacy Benefit Managers

06/18/2019

Nicolas Ferreyros ;

The Centers for Medicare & Medicaid Services (CMS) recently released a final rule for Medicare Part D that codified its decision to allow Medicare Advantage plans to use step therapy, or “fail first,” for new...

The...

06/18/2019

Journal of Clinical Pathways

Pharma Insights

Evolution of Hub Services

06/18/2019

Chrysanthe Peteros , MPH;

Larry Blandford , PharmD;

Chris Dillon , BS ;

What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...

What...

06/18/2019

Journal of Clinical Pathways

Business of Pathways

Cell and Gene Therapies: Paying It Forward and Adjusting Payment Systems for the Age of Cures

06/18/2019

Ira Klein , MD, MBA, FACP;

Sean McElligott , MS;

Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...

Cell...

06/18/2019

Journal of Clinical Pathways

Editor's Page

Managing a Successful Pathways Program

05/15/2019

Winston Wong , PharmD;

Many oncology practices have adopted clinical pathways over the last 5 years with varying degrees of success. These mixed results may stem from a lack of understanding or full commitment from practices in terms of...

Many...

05/15/2019

Journal of Clinical Pathways

Clinical Pathways GPS

CMS Policies Concerning CAR T-Cell Therapy

05/15/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Chimeric antigen receptor (CAR) T-cell therapy is a new form of cancer therapy that uses a patient’s own immune system to fight the disease. This type of cell therapy uses an individualized process to develop a...

...

05/15/2019

Journal of Clinical Pathways

Pharma Insights

The Health Care Ecosystem and Social Determinants of Health: Surveys Suggest the Stage Is Set for Novel Collaborations

05/15/2019

Larry Blandford , PharmD;

Maureen Hennessey , PhD, CPCC, CPHQ;

Dr Hennessey relates her past personal experience with cancer care delivery when her mother was receiving chemotherapy for lung cancer, where an issue with care access could have significantly altered her mother’s...

Dr...

05/15/2019

Journal of Clinical Pathways

Editor's Page

Clinical Practice Guideline Adherence and Real-Time Interventions in Care

04/16/2019

Winston Wong , PharmD;

Clinical practice guidelines (CPGs) in oncology provide a collation of evidence-based, consensus-driven clinical treatment and management best practices to assist physicians in making difficult treatment decisions...

...

04/16/2019

Journal of Clinical Pathways

Editorial

Busting the Myth of “Perverse Physician Incentives” to Prescribe High-Cost Drugs

04/16/2019

Nicolas Ferreyros ;

As proposals directed at reducing the cost of prescription drugs are being discussed at the national level, the Community Oncology Alliance (COA) has taken a closer look at the assertion that oncologists who...

As...

04/16/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Engaging Patients in Care Through Greater Access to Medical Records and Clinical Pathways

04/16/2019

Kristin LaBounty Phillips , MPH;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Shay L. Ashline , PhD;

Matthew Pakizegee , PharmD, MS;

Without interoperability of medical records between health systems, patients are the best chance for the medical system to provide continuity of care when medical records from a different health system are difficult...

...

04/16/2019

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products